ACTRN12616000249459已完成未知
A randomised controlled trial evaluating the impact of an online multi-disciplinary pain management program ('Reboot Online') for chronic pain.
St Vincent's Hospital0 个研究点目标入组 100 人开始时间: 2016年2月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •*Self-identified as experiencing persistent pain for more than 3 months.
- •*Meet criteria for chronic pain.
- •*Resident in Australia.
- •*18 years and over.
- •*Has access to a computer, internet and a printer.
- •*Prepared to provide name, phone number and address of local general practitioner.
- •*If taking medication, must have been taking it for at least 3 months.
- •*Pain must have been assessed by a doctor within the last 3 months.
- •*Willing to provide informed consent
- •*Fluent in written and spoken English
排除标准
- •*Has not experienced pain for at least 3 months
- •*Has impending medical procedures scheduled within the next 6 months.
- •*Pain has not been assessed by a doctor in the last 3 months.
- •*Actively suicidal.
- •*Currently experiencing a psychotic mental illness or bipolar disorder.
- •*Not fluent in English (written and spoken).
- •*Currently experiencing severe depression symptoms
- •*Completed a group-based pain management program within the past 6 months
- •*Not willing to provide local GP contact details.
研究者
相似试验
招募中
2 期
The effects of cannabidiol (CBD) on psychosocial stress, situational anxiety and nausea experienced in a virtual reality environmentPsychosocial stressSituational anxietyCybersicknessMental Health - AnxietyMental Health - Other mental health disordersMotion sicknessACTRN12623000872639niversity of Sydney74
进行中（未招募）
1 期
Tralokinumab monotherapy for adolescent subjects with moderate-to-severe atopic dermatitis - ECZTRA 6Atopic DermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2017-005143-33-PLEO Pharma A/S301
进行中（未招募）
1 期
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthmaSubjects with severe asthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002513-27-ESGlaxoSmithKline, S.A.544
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel-group, multicenterstudy to demonstrate improvement of symptoms of RLS in subjects withmoderate to severe idiopathic RLS with daytime symptoms who takeoxycodone/naloxone prolonged release (OXN PR) compared to subjects takingplacebo (PLA).Estudio multicéntrico, aleatorizado, con doble anonimato, controlado conplacebo, en grupos paralelos, para demostrar la mejoría de los síntomas delsíndrome de las piernas inquietas (RLS) en pacientes con RLS idiopático, demoderado a grave, con síntomas diurnos, que toman oxicodona/naloxona deliberación prolongada (OXN PR), comparados con el grupo tratado con placebo(PLA).Sindrome de Piernas inquietasRestless Legs SyndromeMedDRA version: 12.0Level: LLTClassification code 10058920Term: Restless legs syndromeEUCTR2009-011107-23-ESMundipharma Research GmbH & Co. KG300
进行中（未招募）
1 期
A study of mepolizumab (study medicine) as an add-on therapy in subjects with severe uncontrolled asthma.Subjects with severe asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002513-27-EEGlaxoSmithKline Research & Development Ltd544